Literature DB >> 15701552

Yellow fever and Japanese encephalitis vaccines: indications and complications.

Anthony A Marfin1, Rachel S Barwick Eidex, Phyllis E Kozarsky, Martin S Cetron.   

Abstract

Appropriate administration of yellow fever or Japanese encephalitis vaccines to travelers requires an assessment of the traveler's risk for infection with these vector-borne flaviviruses during their travels and the presence of risk factors for adverse events following immunization. Japanese encephalitis and yellow fever vaccines have been more frequently associated with serious adverse events following immunization since the early 1980s and the late 1990s, respectively. This article describes the adverse events, the magnitude of their risk, and associated risk factors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15701552     DOI: 10.1016/j.idc.2004.11.004

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  8 in total

1.  Meningomyeloradiculitis following yellow fever 17D vaccination: a case report.

Authors:  Rody El Nawar; Perrine Bayle; Andrei Girbovan; Stephanie Juillet Marque; Jerome Servan; Fernando Pico
Journal:  J Neurovirol       Date:  2018-07-09       Impact factor: 2.643

2.  Hospital-based surveillance for Japanese encephalitis at four sites in Bangladesh, 2003-2005.

Authors:  M Jahangir Hossain; Emily S Gurley; Susan Montgomery; Lyle Petersen; James Sejvar; Marc Fischer; Amanda Panella; Ann M Powers; Nazmun Nahar; A K M Rafique Uddin; M Ekhlasur Rahman; A R M Saifuddin Ekram; Stephen P Luby; Robert F Breiman
Journal:  Am J Trop Med Hyg       Date:  2010-02       Impact factor: 2.345

3.  JE Nakayama/JE SA14-14-2 virus structural region intertypic viruses: biological properties in the mouse model of neuroinvasive disease.

Authors:  Thomas J Chambers; Deborah A Droll; Xiaoshan Jiang; William S M Wold; Janice A Nickells
Journal:  Virology       Date:  2007-05-22       Impact factor: 3.616

Review 4.  Vaccines and Guillain-Barré syndrome.

Authors:  Penina Haber; James Sejvar; Yann Mikaeloff; Frank DeStefano
Journal:  Drug Saf       Date:  2009       Impact factor: 5.228

5.  Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial.

Authors:  Ki Wook Yun; Hoan Jong Lee; Jin Han Kang; Byung Wook Eun; Yae-Jean Kim; Kyung-Hyo Kim; Nam Hee Kim; Young Jin Hong; Dong Ho Kim; Hwang Min Kim; Sung-Ho Cha
Journal:  BMC Infect Dis       Date:  2015-01-08       Impact factor: 3.090

Review 6.  Yellow fever vaccine and risk of developing serious adverse events: a systematic review.

Authors:  Ruben Porudominsky; Eduardo H Gotuzzo
Journal:  Rev Panam Salud Publica       Date:  2018-06-05

Review 7.  Immunization in travel medicine.

Authors:  Suzanne Moore Shepherd; William Hudson Shoff
Journal:  Prim Care       Date:  2011-12       Impact factor: 2.907

8.  Use of Japanese encephalitis vaccine in US travel medicine practices in Global TravEpiNet.

Authors:  Bhushan R Deshpande; Sowmya R Rao; Emily S Jentes; Susan L Hills; Marc Fischer; Mark D Gershman; Gary W Brunette; Edward T Ryan; Regina C LaRocque
Journal:  Am J Trop Med Hyg       Date:  2014-07-28       Impact factor: 2.345

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.